Jiangsu Sihuan Bioengineering

Jiangsu Sihuan Bioengineering is a long-established Chinese biopharmaceutical company primarily focused on the research, development, and production of recombinant protein therapeutics. The company operates through its key subsidiary, Beijing Sihuan Bio-Pharmaceutical, which produces a range of biologic products including Interleukin-2, Interferon α2b, and Granulocyte Colony-Stimulating Factor. These products are primarily indicated for the treatment of various cancers, viral hepatitis, and hematological conditions. In addition to its core healthcare business, the company has diversified interests in ecological forestry and agricultural management. Jiangsu Sihuan Bioengineering is a publicly traded entity on the Shenzhen Stock Exchange and maintains GMP-certified manufacturing facilities. The company serves as a significant player in the domestic Chinese market for cytokine-based therapies.